Aptevo Therapeutics Shares Outstanding 2014-2022 | APVO

Aptevo Therapeutics shares outstanding from 2014 to 2022. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
Aptevo Therapeutics Annual Shares Outstanding
(Millions of Shares)
2021 5
2020 3
2019 3
2018 2
2017 2
2016 1
2015 1
2014
2013
Aptevo Therapeutics Quarterly Shares Outstanding
(Millions of Shares)
2022-06-30 5
2022-03-31 5
2021-12-31 5
2021-09-30 5
2021-06-30 5
2021-03-31 4
2020-12-31 3
2020-09-30 3
2020-06-30 3
2020-03-31 3
2019-12-31 3
2019-09-30 3
2019-06-30 3
2019-03-31 2
2018-12-31 2
2018-09-30 2
2018-06-30 2
2018-03-31 2
2017-12-31 2
2017-09-30 2
2017-06-30 2
2017-03-31 1
2016-12-31 1
2016-09-30 1
2016-06-30 1
2016-03-31 1
2015-12-31
2015-09-30 1
2015-06-30 1
2014-12-31
2013-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.015B $0.012B
Aptevo Therapeutics Inc. is a biotechnology company which focused on developing oncology and hematology therapeutics. The company's platform consists of ADAPTIR(TM). Its product pipeline includes WinRho (R) SDF, HepaGam B (R), VARIZIG(R) and IXINITY (R) which are in pre-clinical stage. Aptevo Therapeutics Inc. is based in Seattle, Washington.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $151.795B 9.21
GSK (GSK) United Kingdom $59.851B 7.19
Bio-Rad Laboratories (BIO.B) United States $12.433B 27.47
Biohaven Pharmaceutical Holding (BHVN) United States $10.831B 0.00
QIAGEN (QGEN) Netherlands $9.374B 15.70
Ginkgo Bioworks Holdings (DNA) United States $5.569B 0.00
Arcus Biosciences (RCUS) United States $1.888B 36.85
Myovant Sciences (MYOV) United Kingdom $1.723B 0.00
Emergent Biosolutions (EBS) United States $1.047B 6.07
ADC Therapeutics SA (ADCT) Switzerland $0.370B 0.00
Zymeworks (ZYME) Canada $0.356B 0.00
Enzo Biochem (ENZ) United States $0.109B 0.00
Gelesis Holdings (GLS) United States $0.078B 0.00
SQZ Biotechnologies (SQZ) United States $0.067B 0.00
Ambrx Biopharma (AMAM) United States $0.042B 0.00